National Health Investors Azioni (NYSE: NHI)

Ultime notizie per National Health Investors (NYSE:NHI) Azioni

NATL HEALTH INVESTORS INC

National Health Investors

National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments, i.e., Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment, which generates maximum revenue, consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived in the form of rental income, mortgage and other notes receivable interest income, and resident fees and services.

National Health Investors, Inc. Common Stock

National Health Investors Inc

NewHold Investment Corp III - Class A Ordinary shares

NewHold Investment Corp III

NantHealth Inc

In the current market session, National Health Investors Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) stock price is at $75.00, after a 1.15% drop. However, over the past month, the company's stock increased by 5.62%, and in the past year, by 16.76%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1746817226_0_0.png" alt="Past Year Chart" />

<h3>Evaluating National Health Investors P/E in Comparison to Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
National Health Investors has a lower P/E than the aggregate P/E of 69.62 of the Helath Care REITs industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1746817226_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

News

Intraday Update

Markets

P/E Ratio Insights for National Health Investors

National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) raises FY2025 FFO guidance from $4.59-$4.66 to $4.68-$4.73 vs $4.65 analyst estimate..

Guidance

National Health Investors Raises FY2025 Normalized FFO Guidance from $4.59-$4.66 To $4.68-$4.73 vs $4.65 Est

National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) raises FY2025 NAREIT FFO guidance from $4.59-$4.66 to $4.64-$4.70 vs $4.65 analyst estimate.

National Health Investors Raises FY2025 NAREIT FFO Guidance from $4.59-$4.66 to $4.64-$4.70 vs $4.65 Est

National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) reported quarterly earnings of $1.15 per share which beat the analyst consensus estimate of $1.13 by 1.77 percent. This is a 2.68 percent increase over earnings of $1.12 per share from the same period last year. The company reported quarterly sales of $89.30 million which beat the analyst consensus estimate of $84.76 million by 5.36 percent. This is a 9.55 percent increase over sales of $81.51 million the same period last year.

Earnings

Earnings Beats

National Health Investors Q1 FFO $1.15 Beats $1.13 Estimate, Sales $89.30M Beat $84.76M Estimate

ACEL

ADEA

ADUS

AESI

AMRC

AOMR

AORT

ARES

AROC

AXSM

BCRX

BCSF

BFAM

BNTX

BRBR

BRCC

BWXT

CERT

CORT

CRBG

CRGY

CSTL

CTRA

DENN

DMRC

DORM

EKSO

ESCA

EVER

FANG

FRPT

GBDC

GECC

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HSIC

HSII

HSTM

IART

ICHR

INSP

IPAR

IRMD

JBTM

JELD

JRVR

LSCC

MATX

MYPS

NBIX

NGVT

NMFC

NSSC

NVTS

OCUL

OPAD

OTTR

PLMR

PLOW

PLTR

PLYA

PRAA

PRIM

RAIL

RAND

Earnings Scheduled For May 5, 2025

National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) is preparing to release its quarterly earnings on Monday, 2025-05-05. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect National Health Investors to report an earnings per share (EPS) of $1.13.
National Health Investors bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings History Snapshot</h3>
Last quarter the company beat EPS by $0.02, which was followed by a 0.17% drop in the share price the next day.
Here's a look at National Health Investors's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.10</td>
<td>1.08</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.12</td>
<td>1.03</td>
<td>1.18</td>
<td>1.12</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<h3>Tracking National Health Investors's Stock Performance</h3>
Shares of National Health Investors were trading at $75.37 as of May 01. Over the last 52-week period, shares are up 17.99%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Insights Shared by Analysts on National Health Investors</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on National Health Investors.
The consensus rating for National Health Investors is Neutral, derived from 2 analyst ratings. An average one-year price target of $82.0 implies a potential 8.8% upside.
<h3>Analyzing Ratings Among Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Sabra Health Care REIT, American Healthcare REIT and LTC Properties, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Sabra Health Care REIT, with an average 1-year price target of $19.0, suggesting a potential 74.79% downside.</li>
<li>Analysts currently favor an Outperform trajectory for American Healthcare REIT, with an average 1-year price target of $35.4, suggesting a potential 53.03% downside.</li>
<li>Analysts currently favor an Neutral trajectory for LTC Properties, with an average 1-year price target of $38.0, suggesting a potential 49.58% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
The peer analysis summary presents essential metrics for Sabra Health Care REIT, American Healthcare REIT and LTC Properties, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Health Investors</td>
<td>Neutral</td>
<td>7.92%</td>
<td>$82.91M</td>
<td>3.33%</td>
</tr>
<tr>
<td>Sabra Health Care REIT</td>
<td>Neutral</td>
<td>11.60%</td>
<td>$122.51M</td>
<td>1.70%</td>
</tr>
<tr>
<td>American Healthcare REIT</td>
<td>Outperform</td>
<td>12.47%</td>
<td>$112.17M</td>
<td>-1.42%</td>
</tr>
<tr>
<td>LTC Properties</td>
<td>Neutral</td>
<td>4.76%</td>
<td>$49.47M</td>
<td>1.88%</td>
</tr>
</tbody>
</table>

Key Takeaway:
National Health has the highest revenue growth among peers. It also leads in gross profit margin. However, it has the lowest return on equity.
<h3>Delving into National Health Investors's Background</h3>
National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments, i.e., Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment, which generates maximum revenue, consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived in the form of rental income, mortgage and other notes receivable interest income, and resident fees and services.
<h3>Financial Insights: National Health Investors</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: National Health Investors's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 7.92%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: National Health Investors's net margin is impressive, surpassing industry averages. With a net margin of 50.39%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.33%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): National Health Investors's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.7%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.84.
<a href="https://www.benzinga.com/quote/NHI/earnings">To track all earnings releases for National Health Investors visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Exploring National Health Investors's Earnings Expectations

National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) is a real estate investment trust specializing in sale, leasebacks, joint-ventures, senior housing operating partnerships, and mortgage and mezzanine financing of need-driven and discretionary senior housing and medical investments.
It is set to report its Q1 2025 earnings on May 5. Wall Street analysts expect the company to post EPS of $1.13, up from $1.12 in the prior-year period. According to Benzinga Pro, quarterly revenue is expected to reach $85.13 million, up from $81.51 million a year earlier.
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.</li>
</ul>
<h2 class="wp-block-heading">If You Bought National Health Investors Stock 10 Years Ago</h2>
The company's stock traded at approximately $70.66 per share 10 years ago. If you had invested $10,000, you could have bought roughly 142 shares. Currently, shares trade at $70.20, meaning your investment's value could have declined to $9,935 from stock price depreciation. However, National Health Investors also paid dividends during these 10 years.&nbsp;
National Health Investors' dividend yield is currently 5.04%. Over the last 10 years, it has paid about $38.91 in dividends per share, which means you could have made $5,507 from dividends alone.&nbsp;
Summing up $9,935 and $5,507, we end up with the final value of your investment, which is $15,442. This is how much you could have made if you had invested $10,000 in National Health Investors stock 10 years ago. This means a total return of 54.42%. However, this figure is significantly less than the S&amp;P 500 total return for the same period, which was 193.10%.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a>
<h2 class="wp-block-heading">What Could The Next 10 Years Bring?&nbsp;</h2>
National Health Investors has a consensus rating of "Hold" and a price target of $68 based on the ratings of 14 analysts. The price target implies a more than 3% potential downside from the current stock price.
On Feb. 25, the company announced its Q4 2024 earnings, posting FFO of $1.12, compared to the consensus of $1.11, and revenues of $85.75 million, compared to the consensus of $82.67 million, as reported by <a href="https://www.benzinga.com/news/earnings/25/02/43957300/national-health-investors-q4-2024-ffo-1-12-beats-1-11-estimate-sales-85-75m-beat-82-67m-estimate">Benzinga.</a>
&#8220;The fourth quarter results exceeded our internal expectations as fundamentals remain strong throughout the portfolio with continued improvement in EBITDARM coverage trends, year-over-year cash rental income growth of 8.6%, SHOP NOI growth of 12.5%, and positive contributions from acquisitions completed during the year,&#8221; said CEO Eric Mendelsohn.
See Also: If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?
The company provided its full-year 2025 guidance, expecting normalized FFO attributable to common stockholders in the range of $214.7 million to $218.1 million.
Given the expected downside potential, growth-focused investors may not find National Health Investors stock attractive. Conversely, the stock can be a good option for income-focused investors, who can benefit from the company's solid dividend yield of 5.04%.
Check out this <a href="https://www.benzinga.com/personal-finance/25/04/44659667/why-manpowergroup-regions-financial-and-nexstar-mediaare-winners-for-passive-income">article by Benzinga</a> for three more stocks offering high dividend yields.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/vatom-adv">Invest in the Future of Digital Engagement. Own a Piece of the $100 Billion Metaverse Today for Just $500.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>
National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) is a real estate investment trust specializing in sale, leasebacks, joint-ventures, senior housing operating partnerships, and mortgage and mezzanine financing of need-driven and discretionary senior housing and medical investments.
It is set to report its Q1 2025 earnings on May 5. Wall Street analysts expect the company to post EPS of $1.13, up from $1.12 in the prior-year period. According to Benzinga Pro, quarterly revenue is expected to reach $85.13 million, up from $81.51 million a year earlier.
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.</li>
</ul>
<h2 class="wp-block-heading">If You Bought National Health Investors Stock 10 Years Ago</h2>
The company's stock traded at approximately $70.66 per share 10 years ago. If you had invested $10,000, you could have bought roughly 142 shares. Currently, shares trade at $70.20, meaning your investment's value could have declined to $9,935 from stock price depreciation. However, National Health Investors also paid dividends during these 10 years.&nbsp;
National Health Investors' dividend yield is currently 5.04%. Over the last 10 years, it has paid about $38.91 in dividends per share, which means you could have made $5,507 from dividends alone.&nbsp;
Summing up $9,935 and $5,507, we end up with the final value of your investment, which is $15,442. This is how much you could have made if you had invested $10,000 in National Health Investors stock 10 years ago. This means a total return of 54.42%. However, this figure is significantly less than the S&amp;P 500 total return for the same period, which was 193.10%.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a>
<h2 class="wp-block-heading">What Could The Next 10 Years Bring?&nbsp;</h2>
National Health Investors has a consensus rating of "Hold" and a price target of $68 based on the ratings of 14 analysts. The price target implies a more than 3% potential downside from the current stock price.
On Feb. 25, the company announced its Q4 2024 earnings, posting FFO of $1.12, compared to the consensus of $1.11, and revenues of $85.75 million, compared to the consensus of $82.67 million, as reported by <a href="https://www.benzinga.com/news/earnings/25/02/43957300/national-health-investors-q4-2024-ffo-1-12-beats-1-11-estimate-sales-85-75m-beat-82-67m-estimate">Benzinga.</a>
&#8220;The fourth quarter results exceeded our internal expectations as fundamentals remain strong throughout the portfolio with continued improvement in EBITDARM coverage trends, year-over-year cash rental income growth of 8.6%, SHOP NOI growth of 12.5%, and positive contributions from acquisitions completed during the year,&#8221; said CEO Eric Mendelsohn.
See Also: If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?
The company provided its full-year 2025 guidance, expecting normalized FFO attributable to common stockholders in the range of $214.7 million to $218.1 million.
Given the expected downside potential, growth-focused investors may not find National Health Investors stock attractive. Conversely, the stock can be a good option for income-focused investors, who can benefit from the company's solid dividend yield of 5.04%.
Check out this <a href="https://www.benzinga.com/personal-finance/25/04/44659667/why-manpowergroup-regions-financial-and-nexstar-mediaare-winners-for-passive-income">article by Benzinga</a> for three more stocks offering high dividend yields.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/vatom-adv">Invest in the Future of Digital Engagement. Own a Piece of the $100 Billion Metaverse Today for Just $500.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>

Personal Finance

If You Invested $10K In National Health Investors Stock 10 Years Ago, How Much Would You Have Now?

National Health Investors Acquires $63.5 Million Memory Care Portfolio In Nebraska, Expanding Senior Living Investments

Truist Securities analyst Michael Lewis maintains National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) with a Hold and raises the price target from $70 to $76.

Price Target

Analyst Ratings

Truist Securities Maintains Hold on National Health Investors, Raises Price Target to $76

Wedbush analyst Richard Anderson reiterates National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) with a Outperform and maintains $88 price target.

Reiteration

Wedbush Reiterates Outperform on National Health Investors, Maintains $88 Price Target

Juniper Village at Paramus, a community with 98 assisted living units and 22 memory care units, has been operated by Juniper Communities, an operator of 28 senior housing communities across five states, since February 2021.&nbsp;

Health Care

General

National Health Investors Invested $46.3M To Acquire Juniper Village At Paramus, A Senior Housing Community In Bergen County, NJ

On March 5, it was revealed in an SEC filing that ROBERT MCCABE JR, Director at National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) executed a significant exercise of company stock options.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000877860/000112760225008392//Archives/edgar/data/877860/000112760225008392/0001127602-25-008392-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday showed that JR, Director at National Health Investors, a company in the Real Estate sector, just exercised stock options worth 0 shares of NHI stock with an exercise price of $0.0.
The Thursday morning update indicates National Health Investors shares down by 1.66%, currently priced at $72.18. At this value, JR's 0 shares are worth $0.
<h3>Discovering National Health Investors: A Closer Look</h3>
National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments, i.e., Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment, which generates maximum revenue, consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived in the form of rental income, mortgage and other notes receivable interest income, and resident fees and services.
<h3>National Health Investors's Financial Performance</h3>
Positive Revenue Trend: Examining National Health Investors's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.92% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Real Estate sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 96.68%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): National Health Investors's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 0.96.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.84.
Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 23.45 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 9.66 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 16.94 is below the industry average, indicating that it may be relatively undervalued compared to peers.
</li>
</ul>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>A Deep Dive into Insider Transaction Codes</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000877860">Check Out The Full List Of National Health Investors's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Insider Decision Unfolding At National Health Investors: ROBERT MCCABE JR Exercises Options, Resulting In $0

A significant insider transaction involving the exercise of company stock options was reported on March 5, by CARLTON KEVIN PASCOE, Chief Investment Officer at National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>), as per the latest SEC filing.
What Happened: In an insider options sale disclosed in a Form 4 filing on Wednesday with the <a href="https://www.sec.gov/Archives/edgar/data/0000877860/000112760225008409//Archives/edgar/data/877860/000112760225008409/0001127602-25-008409-index.htm">U.S. Securities and Exchange Commission</a>, PASCOE, Chief Investment Officer at National Health Investors, exercised stock options for 0 shares of NHI. The transaction value amounted to $0.
National Health Investors shares are trading down 1.66% at $72.18 at the time of this writing on Thursday morning. Since the current price is $72.18, this makes PASCOE's 0 shares worth $0.
<h3>Unveiling the Story Behind National Health Investors</h3>
National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments, i.e., Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment, which generates maximum revenue, consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived in the form of rental income, mortgage and other notes receivable interest income, and resident fees and services.
<h3>Financial Milestones: National Health Investors's Journey</h3>
Revenue Growth: National Health Investors's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 7.92%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Real Estate sector.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 96.68%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): National Health Investors's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 0.96.
</li>
</ul>
Debt Management: National Health Investors's debt-to-equity ratio is below the industry average. With a ratio of 0.84, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Insights into Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 23.45 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 9.66, National Health Investors's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 16.94, National Health Investors's EV/EBITDA ratio reflects a below-par valuation compared to industry averages signalling undervaluation
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000877860">Check Out The Full List Of National Health Investors's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Engaging In Insider Activity, CARLTON KEVIN PASCOE At National Health Investors Exercises Options Worth $0

National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) reported quarterly earnings of $1.12 per share which beat the analyst consensus estimate of $1.11 by 0.9 percent. This is a 2.75 percent increase over earnings of $1.09 per share from the same period last year. The company reported quarterly sales of $85.75 million which beat the analyst consensus estimate of $82.67 million by 3.72 percent. This is a 7.91 percent increase over sales of $79.47 million the same period last year.

National Health Investors Q4 2024 FFO $1.12 Beats $1.11 Estimate, Sales $85.75M Beat $82.67M Estimate

AHCO

ALLT

ARQT

AXGN

AXON

BASE

BGFV

BLZE

BTDR

BWIN

CART

CAVA

CBLL

CCCS

CECO

CGBD

CHRD

CIFR

CPNG

CPSS

DAWN

DNUT

DOCN

DRVN

ELAN

EXLS

FIHL

FLYW

FSLR

FULC

GPOR

HRMY

HURN

HYLN

ICCC

IGIC

IMOS

INGN

INTU

INVX

ITRI

IVAC

JACK

JAZZ

KEYS

KNSA

LCID

LGIH

LIVN

LMND

LXFR

MASI

MFIC

MIDD

MMSI

MPLN

MRVI

NOVT

NXRT

Earnings Scheduled For February 25, 2025

Truist Securities analyst Michael Lewis maintains National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) with a Hold and lowers the price target from $78 to $72.

Truist Securities Maintains Hold on National Health Investors, Lowers Price Target to $72

The most oversold stocks in the real estate sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">National Health Investors Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>)</h3>
<ul>
<li>On Nov. 5, the company reported quarterly sales of $82.94 million which beat the analyst consensus estimate of $79.21 million. Eric Mendelsohn, NHI President and CEO, stated, &#8220;Fundamentals remain strong across much of the portfolio with occupancy and EBITDARM coverage improving sequentially from the second quarter across our major asset classes.&#8221; The company's stock fell around 8% over the past month and has a <a href="https://www.benzinga.com/quote/NHI">52-week low of $51.59</a>.</li>
<li>RSI Value: 29.55&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>NHI Price Action: Shares of National Health Investors fell 1.6% to close at $74.35 on Monday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121024&amp;t=be2bearmibe3na1">latest NHI news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="901" height="836" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10045904/image-74.png" alt="" class="wp-image-684847" style="width:674px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10045904/image-74.png 901w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10045904/image-74-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10045904/image-74-768x713.png 768w" sizes="(max-width: 901px) 100vw, 901px" /></a></figure>
<h3 class="wp-block-heading">Site Centers Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SITC#NYSE">SITC</a>)&nbsp;&nbsp;</h3>
<ul>
<li>On Nov. 4, the company said third quarter net income attributable to common shareholders was $320.2 million, or $6.07 per diluted share. &#8220;SITE Centers completed the planned spin-off of Curbline Properties on October 1, unlocking a unique and scalable opportunity focused on convenience real estate and providing investors with two distinct business plans,&#8221; commented David R. Lukes, President and Chief Executive Officer. The company's stock fell around 5% over the past month and <a href="https://www.benzinga.com/quote/DOW">has a 52-week low</a> of $10.19.</li>
<li>RSI Value: 27.10</li>
<li>SITC Price Action: Shares of Site Centers gained 0.6% to close at $15.43 on Monday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121024&amp;t=be2bearmibe3na1">trend in SITC stock</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="906" height="858" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10040454/image-69.png" alt="" class="wp-image-684747" style="width:698px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10040454/image-69.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10040454/image-69-300x284.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10040454/image-69-768x727.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<h3 class="wp-block-heading">Gladstone Land Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAND#NASDAQ">LAND</a>)</h3>
<ul>
<li>On Nov. 15, Gladstone Land announced the retirement of COO Terry Lee Brubaker. President and Chief Executive Officer, David Gladstone, stated, &#8220;Terry has been an integral part of the Gladstone family since inception. His tenure at Gladstone has been marked by remarkable growth and steadfast dedication. Terry&#8217;s commitment to our funds and our shareholders will be missed.&#8221; The company's stock fell around 12% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/LAND">low of $4.68</a>.</li>
<li>RSI Value: 24.17</li>
<li>LAND Price Action: Shares of Braskem fell 5.8% to close at $4.82 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121024&amp;t=be2bearmibe3na1">breakout in LAND shares</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="663" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10040601/image-70.png" alt="" class="wp-image-684748" style="width:630px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10040601/image-70.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10040601/image-70-300x221.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10040601/image-70-768x565.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42389952/top-3-materials-stocks-that-may-rocket-higher-in-december">Top 3 Materials Stocks That May Rocket Higher In December</a></li>
</ul>

Long Ideas

Pre-Market Outlook

LAND

SITC

Top 3 Real Estate Stocks Which Could Rescue Your Portfolio In Q4

NHI is updating its 2024 annual guidance range which includes the following:
NAREIT FFO per diluted common share to a range of $4.39 - $4.41 from $4.50 - $4.54;
Normalized FFO per diluted common share to a range of $4.43 - $4.44 from $4.52 - $4.56; and
Normalized FAD to a range of $201.8 million - $202.5 million from $200.1 million - $201.8 million;
NAREIT FFO and Normalized FFO revised guidance is primarily due to lower cash lease revenue and interest income assumptions, and a $3.6 million non-cash increase to the credit loss reserve attributable to Senior Living Management. This was partially offset by acquisitions closed since August 2024 funded primarily with forward equity proceeds;
Normalized FAD revised guidance is primarily due to acquisitions closed since August 2024 offset by lower cash lease revenue and interest income assumptions attributable to Senior Living Management.

National Health Investors Updates FY24 NAREIT FFO Per Diluted Share From $4.50-$4.54 To $4.39-$4.41; Normalized FFO Per Diluted Share From $4.52-$4.56 To $4.43-$4.44

National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) reported quarterly earnings of $1.03 per share which missed the analyst consensus estimate of $1.08 by 4.63 percent. This is a 4.63 percent decrease over earnings of $1.08 per share from the same period last year. The company reported quarterly sales of $82.94 million which beat the analyst consensus estimate of $79.21 million by 4.72 percent. This is a 3.54 percent increase over sales of $80.11 million the same period last year.

Earnings Misses

National Health Investors Q3 FFO $1.03 Misses $1.08 Estimate, Sales $82.94M Beat $79.21M Estimate

National Health Investors (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nhi#NYSE">NHI</a>) has been on a downward spiral lately with significant selling pressure. After declining 10.2% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.
<h2>How to Determine if a Stock is Oversold</h2>
We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.
RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.
Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock&#39;s price is reaching a point of reversal.
So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefitting from the inevitable rebound.
However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.
<h2>Why a Trend Reversal is Due for NHI</h2>
The heavy selling of NHI shares appears to be in the process of exhausting itself, as indicated by its RSI reading of 28.46. So, the trend for the stock could reverse soon for reaching the old equilibrium of supply and demand.
<img alt="3-month RSI Chart for NHI" class="chart" src="https://staticx-tuner.zacks.com/images/articles/charts/yseop/544/NHI_RCI14.jpeg" style="height:auto; width:100%" title="" />
This technical indicator is not the only factor that calls for a potential rebound for the stock. There is a fundamental indicator as well. A strong agreement among sell-side analysts covering NHI in raising earnings estimates for the current year has led to an increase in the consensus EPS estimate by 0.1% over the last 30 days. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.
Moreover, NHI currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock&#39;s potential turnaround in the near term.
<a href="https://www.zacks.com/stock/news/2350593/here-s-why-national-health-investors-nhi-is-poised-for-a-turnaround-after-losing-10-18-in-4-weeks?cid=CS-BENZ-FT-tale_of_the_tape|rsi-2350593">To read this article on Zacks.com click here.</a>

Mid Cap

Technicals

Here's Why National Health Investors is Poised for a Turnaround After Losing -10.18% in 4 Weeks

Press Releases

NHI Reschedules First Quarter 2025 Earnings Conference Call and Webcast Starting Time

Leading Proxy Advisory Firm Egan-Jones Recommends Stockholders Vote "FOR" All National Health Investors' Director Nominees

NHI Announces First Quarter 2025 Results

NHI Issues Investor Update

Dividends

NHI Announces Second Quarter 2025 Dividend

Independent Proxy Advisory Firm Glass Lewis Recommends National Health Investors Stockholders Vote FOR Both of Land & Buildings' Director Nominees

Leading Independent Proxy Advisory Firm ISS Recommends National Health Investors Stockholders Vote FOR Both of Land & Buildings' Director Nominees

Comments

National Health Investors

Notizie

Ultime notizie per National Health Investors (NYSE:NHI) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO